Colistin–tigecycline versus colistin–imipenem–cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study

Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens

“…A latest study found that the transferability of the mcr-1 gene could be detected in various bacteria, even from animal to healthy people, thus might be one of the reasons that caused rapid prevalence of colistin resistance. [ 35 , 36 ] Moreover, polymyxin has not yet been officially on Chinese market and if we ignore the application of TGC, polymyxin resistance may even be a wide range of outbreaks, let alone its potential nephrotoxicity when used to treat MDR Acinetobacter. [ 37 – 41 ] Given that, the presence of TGC may buffer the colistin-resistant pressure and reduce the enormous threatens.…”

Efficacy of intravenous tigecycline in patients with <em>Acinetobacter </em>complex infections: results from 14 Phase III and Phase IV clinical trials

“…In a review of recent literature, a report on 79 patients in intensive care units with A. baumannii VAP noted that a colistin–tigecycline regimen (in which the tigecycline dose was doubled during the first 48 hours to 100 mg twice a day, and then continued at 50 mg twice a day) vs a colistin–imipenem regimen demonstrated no difference between the two groups in 28-day survival. 21 However, these clinical data in this small retrospective study are still inadequate to draw any definitive conclusions with regard to dosing and treatment of Acinetobacter infections with tigecycline. In a recent prospective observational study comparing a colistin–tigecycline regimen vs a colistin–carbapenem regimen for the treatment of XDR A. baumannii bacteremia, after adjustment for demographic characteristics and comorbidities, it was found that there was excess 14-day mortality only in the colistin–tigecycline subgroup that had an MIC >2 mg/L.…”

“…We have described clinical outcomes and MICs, as well as dosing information from clinical trials, along with a literature review from real-world clinical data and microbiology. While tigecycline may be considered by physicians 14 – 21 as an option for the treatment of patients with MDR Acinetobacter infections alone or in combination with other anti-infective agents when other available antibiotics are not suitable, additional study would be required to properly assess efficacy and determine the correct dosing regimen. 11 – 14 …”

“…The limited data on clinical efficacy of tigecycline against Acinetobacter have mainly come from case reports, case series, or retrospective analyses, 11 – 21 including reports showing that the efficacy of colistin–tigecycline therapy for XDR A. baumannii infections 18 – 20 or A. baumannii ventilator-associated pneumonia (VAP) 21 was comparable to other treatment options (eg, high-dose sulbactam, colistin, high-dose prolonged infusion of a carbapenem, and colistin–imipenem–cilastatin). Nevertheless, the safety and efficacy of tigecycline in treating clinical infections caused by A. baumannii have not been established in adequate and well-controlled clinical trials.…”

Bacillus subtilis from Soybean Food Shows Antimicrobial Activity for Multidrug-Resistant Acinetobacter baumannii by Affecting the adeS Gene

“…Thus, it is critical to understand the mechanism behind the antibiotic-resistant properties of A. baumannii. The medicine used against A. baumannii often leads to widespread antibiotic resistance, including imipenem [6], gentamicin [32], ciprofloxacin [2], ampicillin/sulbactam [5], levofloxacin [36], and tobramycin [31]. To explore the molecular mechanisms of the multidrug resistance in A. baumannii, we investigated the resistancerelated genes in the bacterium: β-lactamase gene (bla…”